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Pegfilgrastim is widely used for the prevention of chemotherapy-induced neutropenia. The development
and use of biosimilar agents help to rationalize healthcare expenditure and improve access to modern
therapies to all who need them. This review focuses on pegfilgrastims with important role in oncology
supportive care. RGB-02 (Gedeon Richter) is a proposed biosimilar to pegylated granulocyte-colony stimu-
lating factor (Neulasta R©, Amgen) with sustained release properties. The clinical analyses in three random-
ized clinical studies provided comparative data between RGB-02 and Neulasta, in a Phase III study patients
receiving docetaxel–doxorubicin chemotherapy treatment equivalence was found. No difference was de-
tected in any safety measure including immunogenicity; treatment switch, from the reference product to
RGB-02 proved safe. Long-acting pegylated filgrastim RGB-02 has successfully accomplished various steps
of biosimilar development.
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Cancer is a major global public health problem, 42 million new diagnoses and 9 million cancer deaths are registered
yearly [1–3]. In Europe, 2635 million cases and 1291 million deaths were counted in 2012 [4]. In the USA, 1,735,350
new cancer cases and 609,640 cancer deaths were predicted for the year 2018 [2]. In Hungary, the total number
of new cases and related deaths in the period 2006–2015 were 712,000 and 331,000, respectively [5]. Incidence
is still rising worldwide while thanks to preventive measures and modern therapies, cancer fatality is decreasing in
well-developed countries [2,4,5]. Since survival in advanced cancer is extended by modern treatments in general, the
prevalence of the disease and the number of patients to be treated are increasing. Taking into account the impact
that cancer makes on life (morbidity and premature death) and its upward trend, it is foreseen that cancer will soon
step to the first place from the second by becoming the disease group that causes the greatest burden [4].
In recent years, great progress has been made in cancer care including medical therapy. New treatment options
such as molecular-targeted therapies and immune therapies frequently based on costly diagnostic methods called
personalized or precision medicine provide improved outcome benefit. Although these sophisticated methods are
increasingly applied in oncology practice, chemotherapy still remains the backbone of systemic treatments. Myelo-
suppressive chemotherapy regimens impair normal hematopoiesis in the bone marrow including the production
of neutrophil granulocytes. Neutropenia increases the risk of infection and may bias therapeutic effectiveness by
causing treatment interruption or delay. The prevention or treatment of neutropenia with granulocyte-colony
stimulating factor (G-CSF, filgrastim) is a standard supportive care measure [6–11]. Filgrastim accelerates the pro-
liferation, maturation and release of neutrophil granulocytes [12]. Filgrastim was first approved in 1991 by the US
FDA [13]. Pegfilgrastim is a pegylated form of filgrastim. The modification of the molecule results in prolonged
bioavailability due to decreased clearance by the kidney when elimination is left almost exclusively to neutrophil
granulocytes [14]. The advantage of long-acting filgrastims such as pegfilgrastim over nonpegylated filgrastims is
that, due to their increased molecular size, they are not eliminated from the body via renal clearance and therefore
their half-life is substantially increased, which allows one single administration per chemotherapy cycle ensuring
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almost complete patient compliance. Pegfilgrastim (Neulasta R©, Amgen) [15] was first approved in 2002 in the
USA and then in Europe [16]. Another pegylated long-acting filgrastim, the lipefilgrastim (Lonquex R©, Teva) [17]
has received regulatory approval and entered the market place in 2013 [18,19]. Pharmacoeconomic analyses showed
that the long-acting filgrastim analog Neulasta was more cost effective and safe than supportive therapy based
on filgrastim [20,21]. All forms bind to the human G-CSF receptor stimulating proliferation, differentiation and
activation of neutrophils. Treatment given subcutaneously starts at least 24 h after the completion of cytotoxic
chemotherapy [22].
As a result of pegylation, pegfilgrastim is administered once-per-cycle, while filgrastim is given once daily, usually
for 7–10 days. It is agreed that filgrastim and pegylated filgrastim have similar efficacy and safety profiles [23–27].
In a literature review, a single dose of pegylated filgrastim was found at least as effective as daily administered
filgrastim [28]. Pegylated filgrastim seemed feasible and safe as primary and secondary prophylaxis in the elderly
population also [29,30]. The use of pegylated filgrastim represents a reliable and convenient option for both patients
and their care givers.
Overview of the market
Health expenditure on cancer increased by >100% in the past 20 years [4]; however, country-specific expenses
vary to a great extent [4,31]. Eastern and central European countries spend about 16–45% of the European average
cancer-related healthcare costs [4,29]. Clearly, in these lower-income countries limited resources are spent to high- or
low-cost medicines either [32,33]. The amount spent on anticancer medicines is predicted to exceed the 140 billion
EUR mark by 2020 globally [34–36]. There is a dilemma how to ensure or improve access to therapy to all patients
and provide them modern care. Biologics are produced in genetically engineered living systems. Costs related to
biologics represent about 20% of all costs in oncology [34–36]. The development and use of biosimilar agents (a
similar version of the originator biologic) provide possibility to rationalize expenses in all healthcare systems. While
biologics are predicted to generate USD 290 billion in revenue and comprise 27% of the pharmaceutical market
by 2020 worldwide, it is foreseen that an expanding proportion of the market will belong to biosimilars [37].
The regulatory process of biosimilar approval in Europe was established earlier than in the USA. Since 2001
when biosimilar legislation emerged >50 biosimilars corresponding to 25 distinct agents have been authorized by
the EMA, most of them being approved in recent years [38]. Further rapid increase in number is foreseen for the
year 2020 when widely utilized originator biologics will lose their patent exclusivity. True biosimilars are approved
in highly regulated regions after passing a rigorous evaluation procedure. Nevertheless, due to the strong need,
many others the so called ‘copy biologics’ are offered in the less regulated markets; for these compounds, no strict
comparability, biosimilarity is demonstrated. This is why at present there are altogether 450 commercialized, which
are ‘following biologics’ worldwide and 250 are in the pipelines [37].
Nevertheless, there are country-specific barriers and concerns among users that delay spread of biosimilars [32,39].
Biosimilar drugs are biological medicines that are highly similar but not identical to already licensed agents, the so
called reference or originator products [35]. High-quality biosimilars are authorized by reputable regulatory agencies
such as the FDA or the EMA provided that comprehensive evaluation indicates similarity between the original
biologic and its biosimilar by means of purity, safety and efficacy [40–42]. Biosimilarity approval is granted on
comparative analytical, preclinical investigations, and clinical data are also required. When the patent on reference
medication expires, biosimilar drugs, if qualify for registration, may come out on the market. The clinical and
economic benefit of the development of biosimilars is twofold: savings for the healthcare budget, and access to
biologics without restriction to all who need them [32,39]. The first filgrastim biosimilar was approved in Europe
in 2008 [41]. At present over 50 biosimilars are approved by EMA [44] among which 7 filgrastim biosimilars are
included (Table 1). Recently biosimilar pegfilgrastims also received EMA (Table 2) [44] and FDA authorization [45]
while some other compounds are in different stages of development.
Two main clinical development approaches can be clearly distinguished in the case of approved biosimilar
pegfilgrastim developments. In the case of the reduced clinical approach (Udenyca R©, Pelmeg R©), only healthy
volunteer studies are conducted and the comparability of the therapeutic effect to Neulasta is concluded on the
basis of the comparable pharmacodynamic response in healthy volunteers. The rationale behind this approach is
that the mechanism of action of pegfilgrastim (i.e., stimulation of neutrophil granulocyte proliferation) is basically
the same in healthy volunteers and patients treated with cytotoxic chemotherapy, hence neutrophil granulocyte
count-related end points in healthy volunteers can be considered as surrogate end points for the conclusion of
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Table 1. EMA-approved filgrastim biosimilars.
Name Active substance Therapeutic area Date of authorization
Accofil R© (Accord Healthcare Ltd.) Filgrastim Neutropenia 18 September 2014
Filgrastim Hexal R© (Hexal) Filgrastim Cancer,
hematopoietic stem cell
transplantation,
neutropenia
6 February 2009
Grastofil R© (Apotex Europe BV) Filgrastim Neutropenia 18 October 2013
Nivestim R© (Hospira) Filgrastim Cancer,
hematopoietic stem cell
transplantation,
neutropenia
8 June 2010
Ratiograstim R©(Ratiopharm) Filgrastim Cancer,
hematopoietic stem cell
transplantation,
neutropenia
15 September 2008
Tevagrastim R© (Teva) Filgrastim Cancer,
hematopoietic stem cell
transplantation,
neutropenia
15 September 2008
Zarzio R© (Sandoz) Filgrastim Cancer,
hematopoietic stem cell
transplantation,
neutropenia
6 February 2009
Table 2. Pegfilgrastim biosimilars with EMA approval or positive CHMP opinion.
Name Active substance Date of authorization
Udenyca R© (ERA Consulting GmbH) Pegfilgastrim 20 September 2018
Pelgraz R© (Accord Healthcare Ltd.) Pegfilgastrim 20 September 2018
Fulphila R© (Mylan) Pegfilgastrim 20 September 2018
Pelmeg R© (Cinfa Biotech S.L) Pegfilgastrim 20 September 2018
Ziextenzo R© (Sandoz GmbH) Pegfilgastrim 20 September 2018
clinical efficacy. In the case of the another approach (Ziextenzo R©, Fulphila R©, Pelgraz R©) extensive clinical program
is conducted with Phase III comparative studies. Therefore, in addition to the comparative pharmacodynamic
data collected in healthy volunteers, with this approach, the equivalent therapeutic effect to Neulasta is directly
demonstrated as well in patient studies similar to the pivotal studies of Neulasta with the same therapeutic
efficacy end points. Moreover, in the case of these developments, the sustained therapeutic effect of the biosimilar
pegfilgrastim is also demonstrated since the patients receive pegfilgratim administrations in each chemotherapy
cycle and the efficacy is evaluated not only in the first cycle but also in the subsequent cycles. The advantage of this
approach is also that it provides extensive patient safety data on the biosimilar product itself in patients, while in
the case of the reduced clinical approach comparable safety in patients is concluded on the basis of biosimilarity
demonstrated at quality and pharmacokinetic (PK)/pharmacodynamic (PD) level.
The approval and introduction of biosimilars to market reduce costs [34,35]. Biosimilar use-generated savings in
healthcare budget may enhance access to new and expensive biologicals and ultimately, improve patients’ health and
quality of life. Since the use of biosimilars is a common interest of different stakeholders including clinicians, payers,
patients and manufacturers, the landscape of medicines in oncology is going to change despite country-specific
barriers and hurdles [32,39].
RGB-02, a proposed biosimilar pegfilgrastim’s development
Introduction to the compound
Filgrastim, approved in 1991 by FDA is a nonglycosylated protein with a methionine group attached to the human
amino acid sequence and is produced by recombinant-DNA technology in Escherichia coli. Filgrastim undergoes
rapid renal clearance and requires daily administration during chemotherapy. In contrast, pegfilgrastim, a covalent
conjugate of filgrastim with a single 20 kDa polyethylene-glycol is mainly eliminated by neutrophil-mediated
clearance, resulting in a long serum half-life and therefore allows single administration per chemotherapy cycle.
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This clear advantage over filgrastim, which has to be administered daily, leads to a better patient compliance
and results in improved clinical outcomes. Development of biosimilars is regulated through specific guidelines to
guarantee similarity with the reference product in quality, PKs, PDs and clinical efficacy as well as the safety profile.
The clinical development program for RGB-02 as a biosimilar drug was set up considering all relevant CHMP
guidelines and Scientific Advices received from the EMA CHMP and European National Authorities, and comprises
to date three randomized, double-blind clinical studies [40–42]:
• A single-center PK/PD study comparing RGB-02 with Neulasta in healthy volunteers (study code 74080).
• A single-center PK/PD study comparing RGB-02 with Neulasta in healthy volunteers (study code: RGB-02-
001).
• A multicentric efficacy and safety study comparing RGB-02 with Neulasta in breast cancer patients (study code:
RGB-02-101, EudraCT number 2013-003166-14).
The originator drug Neulasta [15] sourced from the EU was selected as reference product for all three studies, which
were performed in Europe either as single center in the UK or involving multiple centers in Hungary, Bulgaria,
Croatia, Czech Republic, Romania, Russia, Serbia and Ukraine. The performance and supervision of these clinical
studies followed the principles of Good Clinical Practice as laid down in ICH E 6 [46].
Comparable effects of RGB-02 & Neulasta
Pharmacodynamics
The main purpose of the clinical studies 74080 and RGB-02-001 was to establish the comparative PK profile of
RGB-02 and to investigate PD properties compared with the reference product Neulasta.
For absolute neutrophil count (ANC)-related PD margins, an acceptance range of 85–117.65% was selected for
study 74080 to allow the detection of slight differences. The CI for the primary PD end point (ANC AOBEC0-tlast)
was equivalent to a 95% CI and for the secondary PD end points to a 95.96% CI.
For the subsequent Study RGB-02-001 the comparability acceptance 95% CI range of 80–125% was selected
for the PD analysis following the scientific advice obtained from EMA after analyzing the results from study 74080.
Pegfilgrastim, like filgrastim, induces neutrophil proliferation leading to a marked increase in peripheral blood
neutrophil count within 24 h; this effect can be observed in healthy subjects as well as cancer patients receiving
chemotherapy [27]. The relationship between ANC as a PD parameter and the expected clinical efficacy has led to
ANC being an accepted and established surrogate end point for assessing the effect of G-CSF [47].
Therefore ANC-related PD end points were included in the PK/PD studies for demonstrating biosimilarity
between RGB-02 and Neulasta. The expected results were considered to have a high predictive value for the
subsequent comparative efficacy and safety study (RGB-02-101), which would provide additional supportive
evidence to establish a therapeutically equivalent efficacy of RGB-02 and Neulasta.
Unlike in case of filgrastim, stem cell mobilization is not an approved indication for Neulasta. Nevertheless,
it was decided to measure and compare the progenitor mobilizing effect of RGB-02 with Neulasta in the first
comparative PK/PD study 74080 by assessing blood CD34+ counts. Formal statistical analysis was not planned for
this secondary end point due to the high variability of CD34+ cell count-related parameters. Consequently, in study
74080 the primary PD end point was the area over the baseline effect curve (AOBEC) for absolute neutrophil count
(ANC0-tlast) and the secondary PD end points were ANCmax, ANC Tmax, ANC AUC0-tlast, CD34+ AOBEC0–tlast,
CD34+ AUC0-tlast, CD34+max and CD34+ Tmax; results from this study demonstrated high level of similarity
between RGB-02 and Neulasta based on all PD parameters. Table 3 represents the results for ANC-related end
points of study 74080.
When interpreting results of the first PK/PD study it is important to stress that high level of similarity of PD
end points between RGB-02 and Neulasta has more clinical relevance than the PK parameters. The blood CD34+
count results, although not tested for statistical significance also support the similarity of the two products.
The PD results from study 74080 confirming comparability between the two compounds were used to plan for
a second PK/PD Study RGB-02-001 where PD analysis was selected as primary objective. As primary PD end
points ANC AOBEC0-tlast and ANCmax were selected; parameters for secondary PD end points were ANC Tmax
and ANC AUC0-tlast.
Table 4 presents the results of the second comparative PK/PD study (Study RGB-02-001).
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Table 3. Parametric analysis of comparability for absolute neutrophil counts using -adjusted CIs (pharmacodynamic
population).
Parameter RGB-02 Neulasta R© Ratio‡ -adjusted CI§
N Adjusted mean† N Adjusted mean†
ANC AOBEC0-tlast
(×109.h/l)
96 3490 96 3290 106.12 (99.28, 113.43)
ANC AUC0-tlast
(×109.h/l)
96 5040 96 4920 102.31 (99.83, 104.85)
ANCmax (×109/l) 96 30.463 96 29.242 104.18 (100.60, 107.88)
Results obtained from parametric analysis of loge-transformed pharmacodynamic parameters including terms for treatment, period and sequence fitted as fixed effects, subject fitted as
a random effect and baseline concentrations fitted as a covariate.
†Adjusted geometric mean from ANCOVA.
‡Ratio of adjusted geometric means defined as RGB-02/Neulasta.
§CI for ratio of adjusted geometric means.
ANC: Absolute neutrophil count; ANCOVA: XXX; AOBEC: Area over the baseline effect curve.
Table 4. Parametric analysis of comparability for absolute neutrophil counts (pharmacodynamic population).
Parameter RGB-02 Neulasta R© Ratio‡ CI§
N Adjusted mean† N Adjusted mean†
ANCmax (×109/l) 129 28.585 129 28.632 99.83 (96.06, 103.75)
ANC AOBEC0-tlast
(×109.h/l)
129 3380 129 3350 101.0 (97.21,104.94)
ANC AUC0-tlast
(×109.h/l)
129 4950 129 4880 101.27 (99.01, 103.57)
Results obtained from parametric analysis of loge-transformed pharmacodynamic parameters including terms for treatment, period, sequence and subject within sequence fitted as fixed
effects and baseline concentrations fitted as a covariate.
†Adjusted geometric mean from ANCOVA.
‡Ratio of adjusted geometric means defined as RGB-02/Neulasta.
§CI for ratio of adjusted geometric means.
ANC: Absolute neutrophil count; ANCOVA: XXX; AOBEC: Area over the baseline effect curve.
The results from the second comparative PK/PD Study RGB-02-001 demonstrated high level of similarity
between RGB-02 and Neulasta based on all PD parameters measured.
Overview of clinical efficacy
In order to demonstrate clinical efficacy and safety of RGB-02, a prospective, randomized multicenter, double-blind
study (study code RGB-02-101) was designed and performed in patients with the aim to show comparability with
the originator product Neulasta. The study population, women with breast cancer receiving chemotherapy, was
similar to all three efficacy studies conducted in support of the regulatory approval of Neulasta [48,49]. However,
in order to have an even more homogeneous population for comparison, in line with the principles of biosimilar
development, the study was restricted to patients with stage IIB/III disease, thereby excluding stage IV. Eligible
patients were required to have a performance status of less than Eastern Cooperative Oncology Group 2 and had
to be chemotherapy naive.
The patients were randomized to receive either RGB-02 treatment or Neulasta. The study objectives were selected
to collect sufficient efficacy data for treatment comparison and to collect safety information over a period of time
in order to build a safety database of relevant size.
The chosen study design included a therapeutic switch from Neulasta to RGB-02 in order to maximize patient
exposure to RGB-02 for the longest period of time, thereby increasing the RGB-02 safety database to the largest
possible and also to collect data on the safety of therapy switch from the reference product to RGB-02. Patients
received treatment on a 1:1 randomization basis for the first two chemotherapy cycles and those in the Neulasta
arm were then transferred to RGB-02 treatment for cycles 3 and 4. After completion of four chemotherapy cycles,
there was an option for patients to continue chemotherapy and receive RGB-02 for a further two cycles (cycles 5
and 6) at the discretion of the investigator. Thus, patients in the RGB-02 arm were exposed to the test product for
up to six administrations, whereas patients receiving Neulasta were exposed to two administrations and received
RGB-02 for up to four administrations afterwards. The primary end point in this study was duration of severe
neutropenia (DSN), i.e., the number of days with an ANC <0.5 × 109/l in cycle 1; DSN in cycles 2, 3 and 4
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Figure 1. Mean (± standard deviation) absolute neutrophil count values by day and treatment arm: cycle 1 (per
protocol population).
ANC: Absolute neutrophil count; PP: Per protocol; SD: Standard deviation.
were assessed as secondary end points. Other secondary end points were related to the incidence of severe- and
febrile-neutropenia, time to ANC recovery and depth of ANC nadir, and were used also in the preceding clinical
trials supporting the approval of Neulasta.
The chemotherapy regimen identical to the regimen used in the pivotal Neulasta breast cancer studies comprised
a combined treatment regimen and dose of docetaxel 75 mg/m2 and doxorubicin 60 mg/m2 [25]. This standard
of care regimen constitutes an effective treatment and has been reported to result in an almost 100% incidence
of severe neutropenia with a mean duration of 5–7 days without filgrastim support. Therefore it was considered
appropriate for investigating the therapeutic efficacy of pegfilgrastim without compromising the chemotherapy
treatment outcome in patients [50,51].
Equivalence margins of -1.00 and +1.00 day duration of neutropenia for demonstration of comparable efficacy
between test and reference were applied for the primary end point DSN in cycle 1. Altogether 240 patients had to be
recruited (at least 111 evaluable patients per treatment arm) in order to achieve 90% power at the 5% significance
level.
The clinical results from Study RGB-02-101 clearly confirmed a comparable efficacy of RGB-02 to Neulasta.
The mean ANC values by day and treatment arm during cycle 1 for the cycle population are displayed in Figure 1.
It can be depicted from this figure that the ANC characteristics in cycle 1 are very similar for both compounds; they
have practically the same effect on the ANC count each day indicating similar efficacy of RGB-02 and Neulasta.
Clinical similarity of the two products is fully supported by the primary end point results. The mean and least
squares (LS) mean DSN values in cycle 1 for test and reference were similar, with an LS mean for difference of
0.1 day (Table 5). The lower and upper limits of the CIs for the difference were well within the predefined acceptance
ranges of ±1 day. Therefore, it can be concluded that RGB-02 and Neulasta have an equivalent treatment effect.
The same results could be obtained in cycle 2 where an equivalent sustained treatment effect of RGB-02 and
Neulasta (Table 5) could be shown: the mean and the LS mean DSN values for RGB-02 and Neulasta were similar
and there was no statistically significant difference between the treatments.
The results for cycles 3 and 4, in which all patients received RGB-02, continue to demonstrate the persistence
of efficacy of RGB-02. The results were analyzed according to the initial treatment allocation and the mean DSN
values were <1 day in both cycles and treatment arms, indicating that efficacy of RGB-02 persists and that the
switch from Neulasta to RGB-02 is safe and preserves efficacy.
All other secondary end points showed also very similar results for both treatment groups.
The incidence of severe neutropenia in cycles 1 and 2 was comparable since most of the patients in the first
cycle and approximately half of the patients in the second cycle developed severe neutropenia as expected for the
chemotherapy combination selected for this study.
The observed incidence for febrile neutropenia was low in cycle 1 and similar for RGB-02 and Neulasta, and no
cases of febrile neutropenia were reported in cycle 2. Likewise, a low overall incidence of febrile neutropenia was
observed for both treatment groups and there was no statistically significant difference between the treatments.
The results for time to ANC recovery in cycles 1 and 2 showed that all patients fully recover the neutrophil count
after chemotherapy treatment. Mean values for RGB-02 and Neulasta were similar for each cycle and the median
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Table 5. Duration of severe neutropenia: Study RGB-02-101.
RGB-02 Neulasta R© Difference (RGB-02 – Neulasta)
Cycle 1, PP population
n 112 111
Mean (SD) 1.7 (1.14) 1.6 (1.31)
Least squares mean (95% CI) 1.5 (1.2, 1.8) 1.4 (1.1, 1.7) 0.1 (-0.2, 0.4)
Cycle 1, FAS
n 121 117
Mean (SD) 1.8 (1.28) 1.7 (1.45)
Least squares mean (95% CI) 1.6 (1.3, 1.9) 1.4 (1.1, 1.7) 0.1 (-0.2, 0.4)
Cycle 2, PP population
n 111 100
Mean (SD) 0.7 (0.81) 0.7 (0.97)
Least squares mean (95% CI) 0.7 (0.4, 0.9) 0.6 (0.4, 0.8) 0.1 (-0.2, 0.3)
Cycle 2, FAS
n 117 116
Mean (SD) 0.7 (0.81) 0.9 (1.31)
Least squares mean (95% CI) 0.5 (0.3, 0.8) 0.8 (0.5, 1.0) -0.2 (-0.5, 0.1)
FAS: Full analysis set; PP: Per protocol; SD: Standard deviation.
time to recovery was 3 days in both arms and in both cycles. The depth of ANC nadir calculated as the change
from baseline to the lowest values was also similar for both cycles 1 and 2.
In conclusion, analysis of the primary efficacy end point, DSN in cycle 1 has demonstrated treatment equivalence
between RGB-02 and Neulasta. This is supported by the analysis of all secondary efficacy end points, which revealed
no meaningful differences between the treatment arms.
Overview of safety
The safety profile of RGB-02 is based on cumulated data obtained from 240 healthy subjects receiving a single dose
of RGB-02 in two studies (74080 and RGB-02-001) and from 234 breast cancer patients who received at least one
dose of RGB-02 in this study (Study RGB-02-101).
RGB-02 was well tolerated by all involved subjects and the overall incidence and the adverse event profile for
RGB-02 was similar to that observed in the patients/healthy volunteers who received Neulasta as comparator in
the clinical development program and were consistent with the known safety profile of Neulasta [15]. There was no
evidence of any differences in the immunogenic potential of RGB-02 and Neulasta, and no difference was found
in safety laboratory parameters.
Conclusion
Based on the outcome of preclinical investigations and three randomized, double-blind clinical studies, treatment
equivalence between RGB-02 and Neulasta was demonstrated. Treatment switch from the original agent to the
biosimilar did not raise either efficacy or safety concerns.
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